Haloperidol Depot Hikma Farmacêutica (Portugal) (Haloperidol Decanoate)

Haloperidol Depot Hikma Farmacêutica is indicated for the long‑term management of several psychiatric disorders where sustained dopamine blockade is required.

• Schizophrenia, including maintenance therapy after acute stabilization.
• Acute psychotic episodes when oral therapy is not feasible or adherence is a concern.
• Manic episodes of bipolar disorder that require antipsychotic control.
• Adjunctive treatment in patients with severe agitation or aggression.
• Prevention of relapse in patients with a history of recurrent psychosis.

The safety profile of haloperidol decanoate reflects its dopamine‑blocking activity and includes both frequent, mild reactions and less common, potentially serious events.

Common

• Drowsiness or sedation.
• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Tardive dyskinesia, a potentially irreversible movement disorder.
• Neuroleptic malignant syndrome, characterized by fever, muscle rigidity, and autonomic instability.
• Severe hypotension or cardiac arrhythmias.

Clinicians should evaluate patient history and monitor clinical status when initiating haloperidol depot therapy to minimize risks.

• Assess for cardiovascular disease, as haloperidol can affect QT interval.
• Review history of movement disorders, including Parkinson’s disease or prior tardive dyskinesia.
• Use caution in patients with hepatic or renal impairment; dose adjustments may be required.
• Monitor for signs of neuroleptic malignant syndrome, especially during the first weeks of treatment.
• Evaluate pregnancy and lactation status; the drug’s safety profile in these conditions is not well established.
• Consider potential interactions with other central nervous system depressants.

Haloperidol decanoate may interact with several medications, altering its efficacy or safety.

Avoid

• Concurrent use with other antipsychotics or high‑potency dopamine antagonists, which can increase the risk of extrapyramidal symptoms.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may raise haloperidol plasma levels.
• QT‑prolonging agents such as certain antiarrhythmics, macrolide antibiotics, or antipsychotics, increasing the risk of cardiac arrhythmias.

Use with caution

• CNS depressants including benzodiazepines, opioids, or alcohol, which may enhance sedation.
• Anticholinergic drugs that can mask extrapyramidal side effects.
• Medications that affect electrolyte balance (e.g., diuretics) which may predispose to cardiac effects.